Diet and Lifestyle for Erythrocytosis / Elevated Hematocrit on Testosterone Cypionate: What Actually Works

What is described for high hematocrit on testosterone cypionate?

The 2018 Endocrine Society guideline recommends against starting testosterone therapy in men with elevated hematocrit, and recommends monitoring symptoms, serum testosterone, hematocrit and prostate cancer risk in the first year [6].

Once hematocrit is high, a 2022 review says clinicians will often adjust the testosterone dose, stop therapy, order a phlebotomy, or recommend a combination of these, and notes that the hematocrit cutoffs used in guidelines appear to be arbitrarily chosen [2]. A 2023 consultation guide says providers should decrease or discontinue therapy if hematocrit exceeds 54% until it normalizes [1]. A 2025 systematic review of drug-induced erythrocytosis found no clear consensus among clinicians on diagnosis and management [7].

A 2025 hematology review lists relative polycythemia from volume contraction among the forms of apparent polycythemia to consider when erythrocytosis is found [9].

How much does cypionate raise hematocrit?

The Depo-Testosterone label says androgens have been reported to stimulate red blood cell production by enhancing production of erythropoietic stimulation factor [5]. In a network meta-analysis of 29 placebo-controlled trials and 3,393 men, intramuscular enanthate/cypionate raised mean hematocrit by 4.0% versus placebo (95% CI 2.9 to 5.1); gel raised it 3.0% and patch 1.4%, and intramuscular cypionate/enanthate rose significantly more than patch [3].

A retrospective review of 178 hypogonadal men followed for 3 years found erythrocytosis (hematocrit above 50%) in 66.7% of men on injectable testosterone versus 12.8% on gels; the injectable group was younger, had higher baseline hematocrit, and the study was not randomized [4]. A 2018 review reports that short-acting injectable formulations have the highest incidence of erythrocytosis [8].

What the label says to watch

The Depo-Testosterone label lists polycythemia among adverse reactions and says to check hemoglobin and hematocrit periodically in long-term use [5]. It describes postmarketing venous thromboembolism, says to evaluate leg pain, swelling, warmth and redness for deep vein thrombosis and acute shortness of breath for pulmonary embolism, and says to discontinue treatment with testosterone cypionate if a venous thromboembolic event is suspected [5].